Advert Novartis – Case AUTH/3633/4/22

For providing some, but not all, the relevant information in relation to renal and hepatic impairment in the body of a webpage which was intended to advise health professionals on considerations when using  Entresto (sacubitril/valsartan) which was misleading, Novartis was ruled in breach of the following clauses of the 2021 Code:

Clause 2           - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 5.1        - Failing to maintain high standards

Clause 6.1        - Providing misleading information